Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

P. Sharman, Jeff; Egyed, Miklós; Jurczak, Wojciech; P Skarbnik, Alan; M. Pagel, John; W. Flinn, Ian; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura; Herishanu, Yair; Banerji, Versha; Coutré, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Paolo; Janssens, Ann; Cymbalista, Florence; A. Woyach, Jennifer; Ferrant, Emmanuelle; G. Wierda, William; Munugalavadla, Veerendra; Yu, Ting; Hui Wang, Min; C. Byrd, John

doi:10.1038/s41375-021-01485-x

Public

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Published in Leukemia • Jan 1, 2022

Authors:

Jeff P. Sharman

Miklós Egyed

Wojciech Jurczak

Abstract

Bruton tyrosine kinase (BTK) inhibitors have improved chronic lymphocytic leukemia (CLL) outcomes and offer a chemotherapy-free option [ 1 ]. The BTK inhibitor ibrutinib, alone or with a CD20 antibody, demonstrated better efficacy versus chemoimmunotherapy in treatment-naïve (TN) CLL [ 2 , 3 , 4 ]. ...

Subject

Obinutuzumab

Chlorambucil

Chronic lymphocytic leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!